Development of a specially tailored local drug delivery system for the prevention of fibrosis after insertion of cochlear implants into the inner ear
A cochlear implant (CI)-associated local drug delivery system based on dexamethasone (DMS) was developed with the purpose to inhibit the growth of fibrotic tissue which influences the signal transmission from the CI to the neurons of the inner ear. For the realization of a targeted DMS delivery the following concepts were combined: modification of the silicone-based electrode carrier by incorporation of DMS and a DMS-containing polymeric coating chemically attached on the surface of the electrode carrier. It was demonstrated that the coated CI showed a high coating stability in a simulated implantation procedure. The in vitro drug release studies in a quasi-stationary model revealed a faster DMS release in the initial phase originating from the DMS-containing coatings and then a lower and sustained DMS release originating from the DMS-loaded silicone carrier. The performed in vitro biocompatibility study confirmed that the released DMS was non-toxic for cultured spiral ganglion cells.
KeywordsHigh Performance Liquid Chromatography PLLA Cochlear Implant Environmental Scan Electron Microscopy Silicone Sample
The authors would like to thank Peter Littwin, Martina Schröder and Andrea Rohde for their technical assistance as well as Thilo Storm and Katharina Wulf for their helpful notes and suggestions. Furthermore, the Tepha, Inc. (Lexington, MA, USA) and the Bayer MaterialScience AG (Leverkusen, Germany) are acknowledged for the supply of the polymeric biomaterials P(4HB) and PUR, respectively. This work was funded by the Deutsche Forschungsgemeinschaft (DFG) within SFB Transregio 37 “Mikro- und Nanosysteme in der Medizin–Rekonstruktion biologischer Funktionen” (GZ: TRR 37) and the Bundesministerium für Bildung und Forschung (BMBF) within REMEDIS “Höhere Lebensqualität durch neuartige Mikroimplantate” (FKZ: 03IS2081).
- 2.Furze A, Kralick D, Vakharia A, Jaben K, Graves R, Adil E, Eshraghi AA, Balkany TJ, Van de Water TR. Dexamethasone and methylprednisolone do not inhibit neuritic outgrowth while inhibiting outgrowth of fibroblasts from spiral ganglion explants. Acta Otolaryngol. 2008;128:122–7.CrossRefGoogle Scholar
- 6.Braun S, Ye Q, Radeloff A, Kiefer J, Gstoettner W, Tillein J. Protection of inner ear function after cochlear implantation: compound action potential measurements after local application of glucocorticoids in the guinea pig cochlea. ORL J Otorhinolaryngol Relat Spec. 2011;73:219–28.CrossRefGoogle Scholar
- 8.Borden RC, Saunders JE, Berryhill WE, Krempl GA, Thompson DM, Queimado L. Hyaluronic acid hydrogel sustains the delivery of dexamethasone across the round window membrane. Audiol Neurootol. 2011;16:1–11.Google Scholar
- 13.Arnold W, Senn P, Hennig M, Michaelis C, Deingruber K, Scheler R, Steinhoff HJ, Riphagen F, Lamm K. Novel slow- and fast-type drug release round-window microimplants for local drug application to the cochlea: an experimental study in guinea pigs. Audiol Neurootol. 2005;10:53–63.CrossRefGoogle Scholar
- 16.Jolly C, MedEl. Implantable neuro-stimulation electrode with drug elution material. Patent US 2008/0033520 A1, 2008.Google Scholar
- 17.Dittrich B, Hammann D, Wenzel G, Möller M, Klee D. Dexamethasone releasing cylindrical polydimethyldisiloxane matrices. Biomaterialien (München). 2009;10:61.Google Scholar
- 18.Farahmand Ghavi F, Mirzadeh H, Imani M, Jolly C, Farhadi M. Corticosteroid-releasing cochlear implant: a novel hybrid of biomaterial and drug delivery system. J Biomed Mater Res B Appl Biomater. 2010;94:388–98.Google Scholar
- 19.Jolly C, Garnham C, Mirzadeh H, Truy E, Martini A, Kiefer J, Braun S. Electrode features for hearing preservation and drug delivery strategies. Adv Otorhinolaryngol. 2010;67:28–42.Google Scholar
- 20.Mohammad F, Maryam J, Pirooz S, Farahmand GF, Hesamedin E, Hamid M, Mohammad I, Jolly C. Dexamethasone eluting cochlear implant: Histological study in animal model. Cochlear Implants Int. 2012. doi: 10.1179/17547628MY.0000000024.
- 21.Sternberg K, Kramer S, Nischan C, Grabow N, Langer T, Hennighausen G, Schmitz KP. In vitro study of drug-eluting stent coatings based on poly(l-lactide) incorporating cyclosporine A: drug release, polymer degradation and mechanical integrity. J Mater Sci Mater Med. 2007;18:1423–32.CrossRefGoogle Scholar
- 25.Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR, Belknap SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L, Feldman MD. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006;47(1):175–81.CrossRefGoogle Scholar
- 29.Dexamethason. Arzneistoff-Profile, Basisinformation über arzneiliche Wirkstoffe. Frankfurt am Main: GOVI-Verlag, Pharmazeutischer Verlag; 2009.Google Scholar